Form 4: Alto Neuroscience Director, Christopher Nixon Cox, Acquires Stock Options

Christopher Nixon Cox, a director at Alto Neuroscience, acquired stock options for 15,287 shares of common stock on May 13, 2025.

Summary

• On May 13, 2025, Christopher Nixon Cox, a director of Alto Neuroscience, Inc. (ANRO), acquired stock options to purchase 15,287 shares of common stock.
• The exercise price of these options is $2.37 per share.
• The options vest on the earlier of the one-year anniversary of the grant date or the date of the Issuer's next Annual Meeting following the date of grant, contingent upon continuous service.
• The options expire on May 12, 2035.
• The options were granted pursuant to the Issuer's Non-Employee Director Compensation Policy and were not sold to the reporting person.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects a standard transaction related to director compensation. It doesn't inherently indicate positive or negative performance for the company.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service by the director.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track changes in beneficial ownership.

Stakeholder Impact

• The stock option grant aligns the director's interests with shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates

Keywords

stock options, director, ANRO, Alto Neuroscience, Form 4, beneficial ownership